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Abstract
Background: Rheumatoid arthritis (RA) has been associated with an increased risk of cardiovascular morbidity
and mortality but this has not translated to optimal management of traditional cardiovascular risk factors such as
hyperlipidemia. The objectives of this study were to 1) determine the prevalence of screening for hyperlipidemia
in patients with RA followed by primary care practitioners (PCP); 2) examine initiation of lipid-lowering therapy in
patients with an indication, and 3) assess whether proposed modifications to cardiovascular risk calculations
change the percentage of RA patients with an indication for therapy.
Methods: We performed a retrospective cohort study using an academic medical center-based medical record
database in the United States. Patients with RA defined by the presence of at least one ICD-9 code between
2005–2010 and followed by a PCP within the health care system were included. The positive predictive value of
ICD-9 codes for accurately identifying patients with RA was 96.7 %. Descriptive statistics were used to report the
prevalence of screening and use of lipid-lowering therapy among those with an indication. Factors associated
with not receiving lipid screening were examined using logistic regression models. Indication for and receipt of
therapy were then assessed before and after the application of the European Union League Against Rheumatism
(EULAR) recommended multiplier to the Framingham risk score.
Results: Among 1,056 patients with RA followed by PCPs and eligible for lipid screening, lipid screening was
ordered for 539 (51 %) within the 3-year follow-up period. Patients with diabetes, hypertension, chronic kidney
disease, obesity or age >50 were more likely to be screened. Of those with lipid results (N = 290), 25 (9 %)
patients had an indication for lipid-lowering therapy based on Adult Treatment Panel III guidelines. Ten (40 %)
patients with an indication for lipid-lowering therapy received therapy did not receive therapy. Applying the
EULAR multiplier only changed the indication for lipid-lowering therapy in two patients.
Conclusions: Screening and management of traditional cardiovascular risk factors, including hyperlipidemia,
need to be optimized.
Background
Rheumatoid arthritis (RA) is a chronic inflammatory arth-
ritis that is two to three times more common in women
and is associated with an increased risk of cardiovascular
disease, including myocardial infarction, stroke, and heart
failure [1–4]. Although several studies have clearly demon-
strated this association, it is unclear whether these observa-
tions have impacted the management of cardiovascular
risk factors in RA patients in primary care practice [5]. An
increased focus on screening for cardiovascular risk factors
is especially important given that cardiovascular disease is
the leading cause of mortality in RA patients and presents
about a decade earlier in these patients compared to the
general population [6–8].
The European Union League Against Rheumatism
(EULAR) published recommendations in 2010 for the
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management of traditional cardiovascular risk factors
in patients with RA. EULAR advised physicians to cal-
culate a 10-year coronary heart disease (CHD) risk for
each patient, to multiply this risk by a factor of 1.5, and to
subsequently use the adjusted risk score to manage cardio-
vascular risk in patients with RA [9]. The treatment of RA
as a CHD equivalent has also been proposed to encourage
more aggressive cardiovascular risk management [10–12].
Despite these recommendations, one recent study of RA
patients receiving Medicare benefits demonstrated that
only 45 % were screened for hyperlipidemia [13], and an-
other study of French rheumatology patients revealed that
only 20 of 145 patients were receiving statin therapy [14].
Given this preliminary evidence that knowledge of the
relationship between rheumatoid arthritis and CHD is
not being translated into clinical practice, the present
study aimed to assess the management of hyperlipidemia
among RA patients in a large retrospective cohort of
patients followed by primary care practitioners. More spe-
cifically, the study objectives were: 1) determine the preva-
lence of screening for hyperlipidemia among patients with
RA and describe the characteristics of patients least likely
to be screened, 2) examine whether Adult Treatment
Panel (ATP) III guidelines for the initiation of lipid-
lowering therapy are being followed among those patients
who receive lipid screening, and 3) assess whether
proposed modifications to risk calculations change the
percentage of RA patients that should be receiving
lipid-lowering therapy.
Methods
Study design and setting
We performed a retrospective cohort study among patients
with RA followed by a primary care physician in the
University of Pennsylvania Health System (UPHS) be-
tween January 2005 and February 2010. Only data from
this time period was included in the study. This time
period was chosen for the following reasons: a) most
primary care practices at Penn began using the elec-
tronic medical record in 2004, b) evidence of increased
cardiovascular risk among patients with RA was reported
in the literature during this period, and c) EULAR guide-
lines for the management of cardiovascular risk in RA
were published in February 2010.
Data source
The Penn Data Store (PDS) integrates electronic medical
record data from multiple systems within the University
of Pennsylvania Health System. It includes all discrete
data including diagnostic codes, medications, laboratory
and imaging orders, and most laboratory results within
the inpatient and outpatient medical record systems.
Study population
Rheumatoid arthritis patients were defined by the presence
of at least one International Classification of Diseases ninth
edition (ICD-9) code consistent with RA (ICD9 714.0-
714.33) in the electronic medical record. Cohort entry oc-
curred at the first RA code. Inclusion criteria were age >18
at cohort entry and the receipt of medical care from a pri-
mary care physician (internal medicine, geriatrics, or family
medicine) or physician extender (nurse practitioner or
physician assistant) within UPHS, including two or more
outpatient visits and one year of follow-up time. Follow-up
time ended after a maximum of 3 years from cohort entry.
Patients were excluded if they were less than 18 years
of age at cohort entry or if they were not followed by a
primary care practitioner within UPHS. We additionally
excluded patients on a lipid lowering agent at the time
of cohort entry.
Validation of the exposure
We first performed a validation study to ensure accurate
identification of patients with RA using a single ICD-9
code. Sixty charts were manually reviewed to confirm the
diagnosis of RA using a rheumatologist’s diagnosis as the
gold standard. The positive predictive value of a single
ICD-9 code for RA was 96.7 % (95 % CI: 0.885-0.996).
Outcomes
We examined several outcomes. The first primary out-
come was receipt of an order for lipid screening in the
three years following the first code for rheumatoid arth-
ritis. Lipid screening was defined as ordering of high-
density lipoprotein (HDL) and total cholesterol, or a
lipid panel by the physician. Next, we examined the
prevalence of an indication for therapy determined by
ATP III guidelines that required calculation of the Fra-
mingham Score and presence of a low-density lipopro-
tein (LDL) result (http://www.nhlbi.nih.gov/health-pro/
guidelines/in-develop/cholesterol-in-adults) [15]. LDL
cutoffs, derived from the ATP III guidelines, were
≥190 mg/dl for risk category 0, ≥160 mg/dl for risk
category 1, and ≥130 mg/dl for risk categories 2 and
3. The determination of whether there was an indica-
tion for therapy occurred only in those with
complete data. We then examined receipt of lipid-
lowering medication prescriptions in those that had an in-
dication for such therapy in the one year following the first
set of lipid results. As we used medical record data, the
presence of the prescriptions was evidence of physician in-
tent to prescribe the medication. The medical record does
not contain information on whether the prescription
was filled. Prescribing of a lipid-lowering therapy was
defined as the presence of a prescription of any of the
following: fenofibrate, gemfibrozil, colesevelam, chole-
styramine, ezetimibe, niacin, fish oil, omega 3 fatty acids,
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atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvas-
tatin, and simvastatin. Finally, we applied the EULAR
multiplier (1.5 × the Framingham risk score), recalcu-
lated the ATP III category and the indication for ther-
apy, and then examined the prevalence of therapy
receipt within each category. Of note, the EULAR rec-
ommendation suggests use of this multiplier in patients
meeting two of the following criteria: a) disease dur-
ation of more than ten years, b) rheumatoid factor or
anti-cyclic citrullinated peptide positivity, and c) pres-
ence of extra-articular manifestations [9]. Given the
difficulty of extracting this data without individual
chart reviews, we applied the multiplier to all patients
in the cohort.
Covariates
The following covariates were assessed in the one year
prior to and including cohort entry: age, gender, race,
socioeconomic status based on average income in the
patient’s census track, smoking, alcohol intake, obesity,
hypertension, previous diagnosis of hyperlipidemia, dia-
betes, previous cardiovascular disease (specifically myocar-
dial infarction, stent placement, transient ischemic attack,
and cerebrovascular disease), comorbidities including
chronic kidney disease and peripheral arterial disease,
and medications used for RA including biologic and
non-biologic disease-modifying anti-rheumatic drugs
(DMARDs), non-steroidal anti-inflammatory drugs
(NSAIDs), and corticosteroids. Additionally, we exam-
ined contraindications for lipid-lowering therapy in the
year prior to the first lipid results. These included my-
opathy, pregnancy, liver disease, and use of medications
with interactions including erythromycin, protease inhibi-
tors, itraconazole, and clarithromycin. All medical diagno-
ses were identified by the presence of ICD-9 codes for that
diagnosis. The Framingham risk score was calculated as
previously described and required the presence of the
following variables: age, gender, high-density lipoprotein
(HDL), total cholesterol, systolic blood pressure, use of
anti-hypertensive medications, and tobacco use [15]. Risk
categories were generated based on Framingham risk
scores using ATP III guidelines (http://www.nhlbi.nih.gov/
health-pro/guidelines/current/cholesterol-guidelines/final-
report). Adjusted risk categories were similarly based on
adjusted Framingham risk scores (multiplied by 1.5) using
ATP III guidelines.
Statistical analysis
Percentages were used to describe the prevalence of RA
patients that received lipid screening, the prevalence of
RA patients with an indication for lipid-lowering ther-
apy, and the prevalence of lipid-lowering therapy receipt
within the different risk categories. Percentages were
also employed to characterize the number of patients
with an indication for lipid-lowering therapy after appli-
cation of the EULAR recommended multiplier. We used
logistic regression models to examine the association of
baseline covariates with receipt of screening. We first ex-
amined univariable logistic regression models and then
performed multivariable logistic regression modeling
using only the covariates that were significant at the uni-
variable modeling stage. Covariates were retained in the
final model if they were significantly associated with re-
ceipt of screening (p < 0.1) after adjusting for the other
covariates. The final model’s c statistic was used to de-
scribe the model’s ability to predict not being screened,
and the covariates’ OR and 95%CI were used to describe
the likelihood of not being screened.
Ethics approval
This study was approved by the University of Pennsylvania
Institutional Review Board. As only existing de-identified
data was analyzed, a waiver of written informed consent
was obtained. Children were not included in the study.
This manuscript was prepared in accordance with the
Strobe statement [16].
Results
The study population consisted of 1418 patients with
rheumatoid arthritis. Table 1 provides the baseline char-
acteristics of this population. The patients were predom-
inantly female (85 %) and of age greater than 50 years
(65 %). Among those eligible for screening (N = 1056
patients not on a lipid lowering therapy at entrance into
the cohort), lipid testing was ordered in 539 (51 %)
patients within the 3-year follow-up period, although
not all patients complied with the request for screening.
There was not a significant association between gender
and the performance of lipid screening. Lipid screening
was more likely to be performed in patients of age 50 years
or more (adjusted odds ratio; aOR 1.68, 95 % CI: 1.29-2.18).
Additionally, patients with hypertension (aOR= 2.12, 95 %
CI: 1.35-3.32), diabetes (aOR 2.06, 95 % CI: 1.48-2.87),
obesity (aOR 2.52, 95 % CI:1.51-4.19) were more likely to
be screened (Table 2).
Among patients in whom lipid testing was recom-
mended (N = 593), 290 patients had available lipid re-
sults after excluding patients with a contraindication to
lipid-lowering therapy (N = 30), and those without suffi-
cient data to calculate a Framingham risk score (N = 1)
(Fig. 1). Most patients (65 %) were in the lowest risk cat-
egory (0–1 cardiovascular risk factors), and 32 % of
patients were in the highest risk group with a 10-year
cardiovascular risk greater than 20 %. Very few patients
(3 %) had 2 or more cardiovascular risk factors with a
10-year cardiovascular risk less than 20 %. Among the
290 patients with complete data, the mean total cholesterol
was 190.2 mg/dl (SD 42.2), the mean LDL was 109.4 mg/dl
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(SD 32.4), and the mean HDL was 58.2 mg/dl (SD 20.3).
Mean age at the time of the lipid panel was 61.4 years
(SD 13.5).
When the ATP III guidelines were applied to this group
to determine whether a lipid-lowering medication was indi-
cated based on the patient's LDL value (Table 3), 25 (9 %)
of patients had an indication for therapy, and of those with
an indication, 14 (56 %) received lipid-lowering therapy.
Among all patients prescribed lipid-lowering therapy (with
or without an indication based on ATP III), 53 were pre-
scribed a statin, 3 were prescribed a fibrate, and 15 were
prescribed another class of lipid-lowering medication. After
the EULAR multiplier was applied to the Framingham risk
scores, 3 patients shifted from the lowest risk category to
the highest risk category, and the number of patients with
an indication for therapy increased from 25 to 27. The per-
centage of patients with an indication for therapy that re-
ceived lipid-lowering therapy remained the same (56 %).
Discussion
Given the high burden of cardiovascular disease in patients
with RA, there has been increased emphasis on under-
standing physician screening practices for cardiovascular
risk factors in this patient population [9]. The present
study demonstrated that 51 % of patients received an order
for lipid screening within the 3-year follow-up period.
Screening was significantly less likely to be performed
in patients with an age less than 50; however, those
with concomitant hypertension or diabetes were more
likely to be screened, suggesting attention to traditional
risk factors. While the majority of patients (65 %) in
this study had 0–1 cardiovascular risk factors, 32 % of
patients were in the high-risk category with a 10-year
cardiovascular risk greater than 20 %. Approximately
half of the patients with an indication for lipid-lowering
therapy based on their lipid screening results did not
receive an appropriate pharmacologic treatment dur-
ing the study period. Interestingly, the percentage of
patients that did not receive indicated lipid-lowering
therapy remained essentially the same after applying
the EULAR-recommended risk adjustment.
This study contributes to the growing body of literature
that reflects inadequate cardiovascular screening practices
and suboptimal rates of indicated therapeutic interventions
to modify cardiovascular risk in RA [13, 17]. Our results
regarding inadequate screening mirror those of the Medi-
care population [13] and those in Rochester, MN [17]. In
our study, we were additionally able to observe screening
practices in younger patients with RA and to consider im-
portant contraindications to lipid-lowering therapy. Other
strengths of this study include the use of a medical record
database with access to physician notes that aided in form-
ing a well-defined population and access to lipid values
that allowed for understanding the effect of the EULAR
multiplier on indications for therapy.
The findings in this study have important implications
for the management of patients with RA. Only 51 % of the
patients were screened for lipid levels within the 3-year
follow-up period, and only 56 % received appropriate lipid-
lowering therapy within 1 year of being screened. Possible
quality improvement measures include the education of
primary care physicians about the importance of preventive
cardiovascular care in patients with RA and more effective
coordination of care among rheumatologists, cardiologists,
and primary care physicians in light of the complexity of
this patient population. Enhancing awareness of cardiovas-
cular risk in RA among all care providers would ensure that
collective responsibility is taken for appropriate primary
prevention measures and potentially increase the frequency
Table 1 Patient Demographics (n = 1056)
N (%)
Sex (Female) 893 (85 %)
Age Mean (SD) 55.1 (15.9)
Age <50 years 369 (35 %)
Race White 401 (38 %)
Black 550 (52 %)
Asian 23 (2 %)
Other 58 (5 %)
Unknown/Missing 24 (2 %)
Diagnoses and Risk Factors
Alcohol use 141 (13 %)
Missing Alcohol Status 709 (67 %)
Tobacco use 71 (7 %)
Missing Tobacco Status 708 (67 %)
Hypertensiona 109 (10 %)
Hyperlipidemiaa 16 (2 %)
Diabetes mellitusa 201 (19 %)
Chronic kidney diseasea 13 (1 %)
Cardiovascular diseasea 7 (1 %)
Obesitya 85 (8 %)
Body Mass Index Categories Underweight (<18.5) 11 (<1 %)
Normal (18.5-24.9) 87 (6 %)
Overweight (25–29.9) 102 (7 %)
Obese (≥30) 130 (9 %)
Missing 1,088 (77 %)
Medication Use
NSAIDs 271 (26 %)
DMARDs 330 (31 %)
Corticosteroids 199 (19 %)
All variables assessed at cohort entrance
aDefined by ICD9 code
Abbreviations: NSAIDs Non-steroidal anti-inflammatory drugs, DMARDs Disease
Modifying Antirheumatic Drugs
Jafri et al. BMC Musculoskeletal Disorders  (2015) 16:237 Page 4 of 8
of lipid screening. By increasing awareness of the im-
portance of lipid screening in RA, we can translate our
knowledge about the relationship between RA and car-
diovascular disease into more aggressive cardiovascular
risk management in clinical practice.
In this study, we found that the EULAR modification of
the cardiovascular risk score did not significantly change
the number of patients who had an indication for therapy.
The EULAR recommendations suggested multiplying the
SCORE or Framingham risk score by a factor of 1.5 in
patients with a) disease duration of more than ten years, b)
rheumatoid factor (RF) or anti-cyclic citrullinated pep-
tide antibiody (ACPA) positivity, and c) presence of
extra-articular manifestations [9]. We did not have suffi-
cient information about disease duration, antibody status or
extra-articular manifestations so we applied the 1.5-multi-
plier to all patients. This should have resulted in more
changes than anticipated, thus, the lack of significant
change was interesting. A similar report by Gomez-Vaquero
et al. showed little change in the SCORE algorithms, al-
though a more recent paper by Rosales-Alexander reported
the EULAR multiple did in fact meaningfully change the
risk assessment for patients with an intermediate risk using
SCORE alone [18, 19]. The EULAR multiplier was derived
from expert opinion based on the mean standardized mor-
tality rate of 1.9 for cardiovascular mortality among patients
with established disease [9]. The 1.5 multiplier was felt to be
Fig. 1 Flow Diagram. Among 1418 patients with rheumatoid arthritis
followed by a primary care physician, 1056 were eligible for screening
and 539 received screening. Among those with orders for lipids, 290
had complete lipid panels for analysis after excluding those with
contraindications to therapy. *Contraindications to therapy included
pregnancy (N = 5), myopathy (N = 2), liver disease (e.g. cirrhosis, liver
cancer, alcoholic liver disease, hepatitis C, hepatitis B) (N = 16) or
interacting medications including erythromycin, protease inhibitors,
itraconazole, and clarithromycin (N= 8). Abbreviations: RA = rheumatoid
arthritis, LDL = low density lipoprotein, LLT = lipid lowering therapy
Table 2 Logistic regression for receipt of screening
Univariable Final Multivariable Modela
OR (95 % CI) OR (95 % CI)
Age ≥50 versus <50 1.69 (1.31-2.18) 1.68 (1.29-2.18)
Sex Female vs Male 0.94 (0.68-1.33)
Race Caucasian Ref
Black or African American 1.31 (1.01-1.69)
Asian 0.69 (0.29-1.62)
Other or unknown 0.74 (0.45-1.21)
Hypertension 2.65 (1.72-4.10) 2.12 (1.35-3.32)
Hyperlipidemia Diagnosis 1.61 (0.58-4.46)
Diabetes mellitus 2.22 (1.61-3.07) 2.06 (1.48-2.87)
Obesity 2.62 (1.61-4.27) 2.52 (1.51-4.19)
BMIa 1.04 (1.01-1.07)
BMI Categorya Normal (18.5-24.9) REF
Overweight (25–29.9) 1.66 (0.93-2.96)
Obese (≥30) 2.17 (1.24-3.78)
Underweight (<18.5) 0.40 (0.10-1.62)
Peripheral Arterial Disease 1.92 (0.17-21.3)
Tobacco use Current smoker vs non-smoker or past-smoker (n = 348) 0.70 (0.41-1.18)
The c-statistic (equivalent to area under the curve) for the model was 0.63 for the association between the predicted probabilities and observed responses for the
final multivariable model
aGiven the large amount of missing data for BMI and the risk for selection bias in using a complete case analysis, we have instead used a binary variable for
obesity identified using ICD9 codes. The OR of 1.04 is for each unit increase in BMI
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conservative compared to the 1.9. At the time these recom-
mendations were developed, little evidence existed about
measurement of cardiovascular risk among patients with
RA. Since that time, a handful of studies have now indicated
that the Framingham and SCORE risk scores underestimate
true cardiovascular risk [5, 20–22]. One reason for this is
that inflammation, likely a major contributor to the de-
velopment of atherosclerosis in patients with RA, is not
included [23]. Additional studies are needed to develop
better models for cardiovascular risk stratification spe-
cific to patients with RA [24].
Limitations of the present study should also be recog-
nized. The study was performed at a single center, al-
though the data is likely generalizable to other large
urban academic institutions that serve low-income pop-
ulations. The medical record database used in this study
contained incomplete data on cardiovascular risk factors,
including smoking and body mass index, for some
patients. For instance, if smoking status or alcohol status
were not recorded, they were assumed to be negative;
the absence of such data would likely represent an under-
estimation of cardiovascular risk. Furthermore, the exclu-
sion of patients without complete lipid panels may have
resulted in a selection bias and may reflect the patterns of
certain physicians to record complete data; it may also re-
flect insurance coverage since the laboratory tests for
some patients may not have been performed within the
UPHS system. Additionally, we did not perform detailed
chart reviews for each patient so information on lifestyle
modification and recommendations for hyperlipidemia
were not captured. Finally, screening practices of primary
care physicians were specifically investigated because they
are generally responsible for providing basic preventive
cardiovascular care. Nevertheless, patients could poten-
tially have received lipid screening and prescriptions for
lipid-lowering therapy from outside providers without ac-
curate documentation in our medical record database.
Similarly, only approximately one third of patients were
recorded as having a DMARD recorded during the base-
line period. While this is consistent with other population-
based estimates of DMARD use among patients with RA
in the United States, prescriptions from outside rheuma-
tologists could have been missed [25, 26]. However, during
this time period, there was a system-wide emphasis placed
on medication reconciliation requiring this to be per-
formed at each visit.
Systematic studies of the barriers to lipid screening and
to patient adherence with lipid-lowering therapy will be es-
sential in optimizing long-term outcomes for RA patients.
Although the increased cardiovascular risk in RA may be
mediated by both traditional risk factors and additional risk
factors such as systemic inflammation and a prothrombotic
state [27] a fundamental principle of RA management
should be the modification of traditional risk factors
with the appropriate prescription of lipid-lowering ther-
apy. Both before and after the EULAR adjustment of the
ATP III risk categories, about one-half of the patients in
this study did not receive a basic therapeutic intervention
that was indicated to reduce their cardiovascular risk. A
recent large population-based study of RA patients with
incident statin use demonstrated that statin discontinu-
ation was associated with a 60 % increased risk of cardio-
vascular mortality and a 79 % increased risk of all-cause
mortality [28]. Although it is known that statins have both
cholesterol-lowering effects and potent anti-inflammatory
properties, the “healthy adherer effect” (i.e., more compli-
ant patients engage in healthier behaviors) has also been
postulated to explain the association of statin discontinu-
ation with poorer outcomes such as increased risk of acute
myocardial infarction [29] (17). The mechanisms by which
Table 3 ATP III Risk Category, Indication for Lipid Lowering Therapy, and Receipt of Therapy (n = 290 patients with lipid results)
Before EULAR Adjustment After EULAR Adjustment
Risk Category N (%) Indication for therapy based on LDL N (%) Indication for therapy after adjustment
N (%) N (%)
CHD or CHD Risk Equivalents 92 (32 %) 20 (22 %) 96 (33 %) 23 (24 %)
OR
10 yr risk >20 %
2+ Risk Factors AND 7 (1 %) 1 (50 %) 1 (0.3 %) 0 (0 %)
10-yr risk 10-20 %
2+ Risk Factors AND 2 (2 %) 0 (0 %) 7 (2 %) 0 (0 %)
10-yr risk <10 %
0-1 Risk Factors AND 189 (65 %) 4 (2 %) 186 (64 %) 4 (2 %)
10-yr risk <10 %
Total 290 (100 %) 25 (9 %) 290 (100 %) 27 (9 %)
Indication for therapy in each risk category was based on the ATP III guidelines which suggest the following LDL cutoffs: 190 mg/dl for risk category 0, ≥160 mg/dl for
risk category 1, and ≥130 mg/dl for risk categories 2 and 3.(15)
Jafri et al. BMC Musculoskeletal Disorders  (2015) 16:237 Page 6 of 8
statins influence morbidity and mortality in RA need to be
characterized more specifically, and appropriately powered
prospective studies should be designed to address the
potential for statins to reduce cardiovascular and all-
cause mortality in RA. An analysis of the effects of sta-
tins on cardiovascular risk in this patient population
will be particularly important given that inflammatory
arthritis is not included in the cardiovascular risk cal-
culator recently published by the American College of
Cardiology (ACC) and American Heart Association
(AHA) [30].
Conclusions
In summary, these data highlight the lack of screening for
hyperlipidemia in approximately half of patients with
rheumatoid arthritis and the under-treatment of a simi-
lar percentage of patients who had an indication for
lipid-lowering therapy based on ATP III guidelines prior
to publication of the EULAR recommendations for cardio-
vascular risk management. Regardless of whether primary
care physicians continue to use the ATP III guidelines or
widely adopt the 2013 ACC/AHA guidelines regarding the
use of lipid-lowering therapy, lipid screening is a pre-
requisite for the appropriate assessment of cardiovascular
risk. Further research is needed to address the effective-
ness of interventions to improve lipid screening in patients
with rheumatoid arthritis and also to develop a systematic
approach to characterizing cardiovascular risk in this
patient population.
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